July 10th 2025
Gilead Sciences has partnered with the Global Fund to supply up to 2 million doses of its long-acting HIV prevention drug, lenacapavir, to low and lower-middle income countries.
Model that Decriminalized Drugs, Invests Savings Shows Reduction in HIV Transmission
January 28th 2022The study authors focused on eastern Europe and central Asia in their model, which included 4 scenarios for decriminalizing drug use and investing the savings into HIV transmission-reduction strategies.
Read More
HIV Prevention Plan in Namibia Shows High Prevalence of Risk Factors
December 2nd 2021Study authors from the CDC found that girls in the sub-Saharan country of Namibia are at increased risk for HIV acquisition and also experience risk factors that make them eligible for HIV infection prevention programs.
Read More